Tag: Pharmather - Page 6 - Psychedelic Alpha

Read more about the article PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease

Post published:April 20, 2021
Post category:Press Release

Read more about the article PharmaTher Provides Update on Psychedelic Product Programs

PharmaTher Provides Update on Psychedelic Product Programs

Post published:April 15, 2021
Post category:Press Release

Read more about the article World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor

World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor

Post published:March 16, 2021
Post category:Press Release

Read more about the article PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease

Post published:March 2, 2021
Post category:Press Release

Read more about the article PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

Post published:February 23, 2021
Post category:Press Release

Read more about the article PharmaTher Announces Sale of Psilocybin Program

PharmaTher Announces Sale of Psilocybin Program

Post published:February 17, 2021
Post category:Press Release

Read more about the article PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease

PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease

Post published:February 4, 2021
Post category:Press Release

Read more about the article PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

Post published:February 1, 2021
Post category:Press Release

Read more about the article PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders

Post published:January 19, 2021
Post category:Press Release

Read more about the article PharmaTher Approved to Trade on the OTCQB Venture Market

PharmaTher Approved to Trade on the OTCQB Venture Market

Post published:January 13, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.